Janus Henderson Group PLC Invests $17.10 Million in enGene Holdings Inc. (NASDAQ:ENGN)

Janus Henderson Group PLC purchased a new stake in shares of enGene Holdings Inc. (NASDAQ:ENGN) during the 1st quarter, according to its most recent Form 13F filing with the Securities & Exchange Commission. The fund purchased 1,000,000 shares of the company’s stock, valued at approximately $17,095,000. Janus Henderson Group PLC owned 2.29% of enGene at the end of the most recent quarter.

Several other large investors have also recently bought and sold shares of the business. Vivo Capital LLC bought a new stake in enGene during the 4th quarter valued at approximately $6,264,000. BVF Inc. IL bought a new position in enGene in the 4th quarter valued at $20,777,000. Omega Fund Management LLC bought a new position in shares of enGene in the 4th quarter worth $10,441,000. Finally, Altitude Crest Partners Inc. bought a new position in shares of enGene in the 1st quarter worth $2,039,000. 64.16% of the stock is owned by institutional investors and hedge funds.

Analyst Ratings Changes

Several analysts recently commented on ENGN shares. Wells Fargo & Company began coverage on enGene in a research note on Monday, April 22nd. They set an “overweight” rating and a $30.00 price objective on the stock. Guggenheim initiated coverage on enGene in a report on Monday, April 15th. They set a “buy” rating and a $34.00 price target for the company. Six analysts have rated the stock with a buy rating, According to MarketBeat, the stock has a consensus rating of “Buy” and an average price target of $34.40.

enGene Stock Up 6.1 %

Shares of ENGN opened at $9.50 on Thursday. The firm’s fifty day simple moving average is $9.23 and its two-hundred day simple moving average is $12.24. enGene Holdings Inc. has a 12 month low of $6.69 and a 12 month high of $43.00.

enGene (NASDAQ:ENGN) last released its quarterly earnings data on Friday, June 14th. The company reported ($0.38) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.24) by ($0.14). On average, equities research analysts predict that enGene Holdings Inc. will post -1.33 earnings per share for the current year.

enGene Company Profile

enGene Holdings Inc, through its subsidiary enGene, Inc, operates as a clinical-stage biotechnology company that develops genetic medicines through the delivery of therapeutics to mucosal tissues and other organs. Its lead product candidate is EG-70 (detalimogene voraplasmid), which is a non-viral immunotherapy to treat non-muscle invasive bladder cancer patients with carcinoma-in-situ (Cis), who are unresponsive to treatment with Bacillus Calmette-Guérin.